Pharmalittle: AMA urged to avoid blanket limits on opioids; in rare move, N.J. officials attack J&J

first_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. By Ed Silverman Nov. 14, 2018 Reprints What is it? What’s included? @Pharmalot About the Author Reprints Hello, everyone, and how are you this fine morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made it this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch …New Jersey officials are taking on a core state industry by filing a lawsuit against a subsidiary of Johnson & Johnson (JNJ) that makes opioids, accusing the company of misleading patients about the addictive dangers posed by its drugs, The New York Times writes. More than 40 state attorneys general have joined a multiyear, wide-ranging investigation of manufacturers and distributors of opioids, but this marks the first time that New Jersey has brought legal action against a company based in the state as it struggles to contain a spiraling opioid addiction crisis. Ed Silverman Alex Hogan/STATcenter_img STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalot Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED GET STARTED Pharmalittle: AMA urged to avoid blanket limits on opioids; in rare move, N.J. officials attack J&J [email protected] Log In | Learn More Tags drug pricinglegalopioidspharmaceuticalspolicySTAT+last_img read more